Business Description
ResMed Inc
NAICS : 339112
SIC : 3841
ISIN : BRR1MDBDR003
Compare
Compare
Traded in other countries / regions
RMD.AustraliaRMD.USARMEA.GermanyRMD.AustriaR1MD34.Brazil0KW4.UKRMD.Mexico IPO Date
2020-01-27Description
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.14 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.38 | |||||
| Debt-to-EBITDA | 1.17 | |||||
| Interest Coverage | 24.43 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.17 | |||||
| Beneish M-Score | -2.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.2 | |||||
| 3-Year EBITDA Growth Rate | 10.4 | |||||
| 3-Year EPS without NRI Growth Rate | 12.6 | |||||
| 3-Year FCF Growth Rate | -7.4 | |||||
| 3-Year Book Growth Rate | 17.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 20.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.28 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 24.95 | |||||
| 12-1 Month Momentum % | 0.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.12 | |||||
| Quick Ratio | 1.81 | |||||
| Cash Ratio | 0.3 | |||||
| Days Inventory | 180.1 | |||||
| Days Sales Outstanding | 56.35 | |||||
| Days Payable | 33.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 4.1 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | -1.53 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.78 | |||||
| Operating Margin % | 27.26 | |||||
| Net Margin % | 21.25 | |||||
| ROE % | 24.14 | |||||
| ROA % | 14.76 | |||||
| ROIC % | 17.77 | |||||
| ROC (Joel Greenblatt) % | 60.29 | |||||
| ROCE % | 21.49 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.48 | |||||
| Forward PE Ratio | 20.92 | |||||
| PE Ratio without NRI | 23.48 | |||||
| Shiller PE Ratio | 36.47 | |||||
| Price-to-Owner-Earnings | 39.34 | |||||
| PEG Ratio | 1.54 | |||||
| PS Ratio | 5 | |||||
| PB Ratio | 5.1 | |||||
| Price-to-Tangible-Book | 26.08 | |||||
| Price-to-Free-Cash-Flow | 37.75 | |||||
| Price-to-Operating-Cash-Flow | 30.46 | |||||
| EV-to-EBIT | 19.48 | |||||
| EV-to-Forward-EBIT | 24.76 | |||||
| EV-to-EBITDA | 16.62 | |||||
| EV-to-Forward-EBITDA | 22.7 | |||||
| EV-to-Revenue | 5.31 | |||||
| EV-to-Forward-Revenue | 7.58 | |||||
| EV-to-FCF | 40.07 | |||||
| Price-to-Projected-FCF | 2.02 | |||||
| Price-to-DCF (Earnings Based) | 2.28 | |||||
| Price-to-DCF (FCF Based) | 5.17 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.53 | |||||
| Price-to-Graham-Number | 5.22 | |||||
| Earnings Yield (Greenblatt) % | 5.14 | |||||
| Forward Rate of Return (Yacktman) % | 17.68 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ResMed Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 21,668.966 | ||
| EPS (TTM) (R$) | 7.831 | ||
| Beta | -0.19 | ||
| Volatility % | 8.31 | ||
| 14-Day RSI | 24.95 | ||
| 14-Day ATR (R$) | 0.000007 | ||
| 20-Day SMA (R$) | 287.97 | ||
| 12-1 Month Momentum % | 0.18 | ||
| 52-Week Range (R$) | 284.2 - 309.97 | ||
| Shares Outstanding (Mil) | 588.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ResMed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ResMed Inc Stock Events
| Event | Date | Price(R$) | ||
|---|---|---|---|---|
| No Event Data | ||||
ResMed Inc Frequently Asked Questions
What is ResMed Inc(BSP:R1MD34)'s stock price today?
The current price of BSP:R1MD34 is R$287.97. The 52 week high of BSP:R1MD34 is R$309.97 and 52 week low is R$284.20.
When is next earnings date of ResMed Inc(BSP:R1MD34)?
The next earnings date of ResMed Inc(BSP:R1MD34) is 2023-10-27 Est..
Does ResMed Inc(BSP:R1MD34) pay dividends? If so, how much?
ResMed Inc(BSP:R1MD34) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers